50. Hansten PD, Tan MS, Horn JR, et al. Colchicine drug interaction errors and misunderstandings: recommendations for improved evidence-based management. Drug Safety. Published online Dec 15, 2022. doi:https://doi.org/10.1007/s40264022-01265-1. 51. Papageorgiou N, Briasoulis A, Lazaros G, Imazio M, Tousoulis D. Colchicine for prevention and treatment of cardiac diseases: A meta-analysis. Cardiovascular Therapeutics. 2016;35(1):10-18. doi:https://doi.org/10.1111/1755-5922.12226. 52. Fradkin A, Yahav J, Zemer D, Jonas A. Colchicineinduced lactose malabsorption in patients with familial Mediterranean fever. Isr J Med Sci. Oct 31,1995;(10):616-20. PMID:7591685. 53. National Institute of Diabetes and Digestive and Kidney Diseases. Eating, diet and nutrition for lactose intolerance. NIDDK. National Institute of Diabetes and Digestive and Kidney Diseases. Published Oct 17, 2019. https://www.niddk.nih. gov/health-information/digestive-diseases/ lactose-intolerance/eating-diet-nutrition. 54. Artom G, Koren-Morag N, Spodick DH, et al. Pretreatment with corticosteroids attenuates the efficacy of colchicine in preventing recurrent pericarditis: a multi-centre all-case analysis. European Heart Journal. 2005;26(7):723-727. doi:https://doi.org/10.1093/eurheartj/ehi197. 55. Lodoco. Package insert. AGEPHA Pharma. 2023. 56. Sammaritano LR, Bermas BL, Chakravarty EE, et al. 2020 American college of rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal D\diseases. Arthritis & Rheumatology. Published online Feb 23, 2020. doi:https://doi.org/10.1002/art.41191. 57. Ozen S, Demirkaya E, Erer B, et al. EULAR recommendations for the management of familial Mediterranean fever. Annals of the Rheumatic Diseases. 2016;75(4):644651. doi:https://doi.org/10.1136/ annrheumdis-2015-208690. 58. Imazio M, Brucato A, Cumetti D, et al. Corticosteroids for recurrent pericarditis. Circulation. 2008;118(6):667-671. doi:https://doi. org/10.1161/circulationaha.107.761064. 59. Spiegel RJ, Oliff AI, Bruton J, Vigersky RA, Echelberger CK, Poplack DG. Adrenal suppression after short-term corticosteroid therapy. The Lancet. 1979;313(8117):630-633. doi:https://doi. org/10.1016/s0140-6736(79)91077-8. 60. Pazderska A, Pearce SH. Adrenal insufficiency – recognition and management. Clinical Medicine. 2017;17(3):258-262. doi:https://doi.org/10.7861/ clinmedicine.17-3-258. 61. Testing-AIC adrenal insufficiency coalition. Accessed May 21, 2024. https://www. adrenalinsufficiency.org/testing/. 62. Imazio M, Brucato A, Maestroni S, et al. Prevalence of c-reactive protein elevation and time course of normalization in acute pericarditis. Circulation. 2011;123(10):1092-1097. doi:https:// doi.org/10.1161/circulationaha.110.986372. 63. Grant JK, Shah NP. The impact of physical activity on pericarditis. Current Cardiology Reports. 2021;23(10). doi:https://doi.org/10.1007/s11886021-01578-0. 64. 2020 ESC guidelines on sports cardiology and exercise in patients with cardiovascular disease. www.escardio.org. https://www.escardio.org/ Guidelines/Clinical-Practice-Guidelines/sportscardiology-and-exercise-in-patients-withcardiovascular-disease. 65. Buckley LF, Libby P. Role of colchicine in cardiovascular disease management. Arteriosclerosis, Thrombosis, and Vascular Biology. Published online Mar 21, 2024. doi:https://doi. org/10.1161/atvbaha.124.319851. 66. Tan MS, Gomez-Lumbreras A, Villa-Zapata L, et al. Colchicine and macrolides: a cohort study of the risk of adverse outcomes associated with concomitant exposure. Rheumatol Int. 2022;42: 2253–2259. https://doi.org/10.1007/s00296-02205201-5. 67. Schwier NC, Cornelio CK, Boylan PM. A systematic review of the drug–drug interaction between statins and colchicine: patient characteristics, etiologies, and clinical management strategies. Pharmacotherapy. 2022; 42:320–333. doi:10.1002/ phar.2674. 68. Hansten PD, Tan MS, Horn JR, Gomez-Lumbreras A, Villa-Zapata L, Boyce RD, Subbian V, Romero A, Gephart S, Malone DC. Colchicine drug interaction errors and misunderstandings: recommendations for improved evidence-based management. Drug Saf. 2023 Mar;46(3):223-242. doi: 10.1007/s40264-022-01265-1. Epub 2022 Dec 15. PMID: 36522578; PMCID: PMC9754312. 69. Imazio M, Pivetta E, Andreis A, Serra C, Carbone F, Masoero M, Ottino M, Ravetti A, Renzetti A, Totaro S, et al. Incessant pericarditis as a risk factor for complicated pericarditis and hospital admission. Circulation. 2021;143:401-402. doi: 10.1161/ CIRCULATIONAHA.120.051156. 70. Andreis A, Imazio M, Casula M, Avondo S, Brucato A. Recurrent pericarditis: an update on diagnosis and management. Internal and Emergency Medicine. Published online Feb 28, 2021. doi:https://doi.org/10.1007/s11739-021-02639-6. 71. Chiabrando JG, Bonaventura A, Vecchié A, et al. Management of acute and recurrent pericarditis. Journal of the American College of Cardiology. 2020;75(1):76-92. doi:https://doi.org/10.1016/j. jacc.2019.11.021]. 72. Imazio M, Brucato A, Maestroni S, et al. Prevalence of c-reactive protein elevation and time course of normalization in acute pericarditis. Circulation. 2011;123(10):1092-1097. doi:https:// doi.org/10.1161/circulationaha.110.986372. 73. Imazio M, Bobbio M, Cecchi E, et al. Colchicine as first-choice therapy for recurrent pericarditis: results of the CORE (COlchicine for REcurrent pericarditis) trial. Arch Intern Med. 2005;165:1987-1991. 74. Valentina Yu. Myachikova, Maslyanskiy AL, Moiseeva OM, et al. Treatment of idiopathic recurrent pericarditis with goflikicept. Journal of the American College of Cardiology. 2023;82(1):30-40. doi:https://doi.org/10.1016/j.jacc.2023.04.046. 75. Buckley LF, Viscusi MM, Van Tassell BW, Abbate A. Interleukin-1 blockade for the treatment of pericarditis. European Heart Journal - Cardiovascular Pharmacotherapy. 2017;4(1):4653. doi:https://doi.org/10.1093/ehjcvp/pvx018. 76. Brucato A, Imazio M, Gattorno M, et al. Effect of anakinra on recurrent pericarditis among patients with colchicine resistance and corticosteroid dependence. JAMA. 2016;316(18):1906. doi:https:// doi.org/10.1001/jama.2016.15826. 77. Klein AL, Imazio M, Cremer P, et al. Phase 3 trial of interleukin-1 trap rilonacept in recurrent pericarditis. New England Journal of Medicine. 2021;384(1):31-41. doi:https://doi.org/10.1056/ nejmoa2027892. 78. Imazio M, Klein AL, Brucato A, et al. Sustained pericarditis recurrence risk reduction with longterm rilonacept. Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease. 2024;13(6):e032516. doi:https://doi.org/ 10.1161/JAHA.123.032516]. 79. Imazio M, Andreis A, De Ferrari GM, et al. Anakinra for corticosteroid-dependent and colchicine-resistant pericarditis: The IRAP (International Registry of Anakinra for Pericarditis) study. Eur J Prev Cardiol. 2020;27:956-964. 80. Imazio M. et al. J Am Heart Assoc. 2024 Mar 19; 13(6): e032516. 81. Imazio M, Lazaros G, Gattorno M, et al. Antiinterleukin-1 agents for pericarditis: a primer for cardiologists. European Heart Journal. Published online Sep 16, 2021. doi:https://doi.org/10.1093/ eurheartj/ehab452. 82. Holroyd CR, Seth R, Bukhari M, et al. The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis. Rheumatology. 2018;58(2):e3-e42. doi:https:// doi.org/10.1093/rheumatology/key208. 83. Singh JA, Saag KG, Bridges SL, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis & Rheumatology. 2015;68(1):1-26. doi:https://doi. org/10.1002/art.39480]. 84. Khandaker MH, Schaff HV, Greason KL, Anavekar NS, Espinosa RE, Hayes SN, Nishimura RA, Oh JK. Pericardiectomy vs medical management in patients with relapsing pericarditis. Mayo Clin Proc. 2012;81:1062-1070. 85. Pryor K, Tarter L, Economy K, et al. Pericarditis management in individuals contemplating pregnancy, currently pregnant, or breastfeeding. Curr Cardiol Rep. Oct 2023;25(10):1103-1111. doi:10.1007/s11886-023-01930-6. 86. Brucato A, Imazio M, Curri S, Palmieri G, Trinchero R. Medical treatment of pericarditis during pregnancy. International Journal of Cardiology. 2010;144(3):413-414. doi:10.1016/j. ijcard.2009.03.028. 87. Sammaritano LR, Bermas BL, Chakravarty EE, et al. 2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. Arthritis Rheumatol. Apr 2020;72(4):529556. doi:10.1002/art.41191. 88. Weber E, Millet A, Beghin D, et al. Safety of canakinumab during pregnancy: seven new cases. Rheumatology. 2022;61(8):e229-e231. doi:10.1093/rheumatology/keac177. 89. Control, cfd interim clinical considerations for use of covid-19 vaccines in the United States. 2024. Available from: https://www.cdc.gov/ vaccines/covid-19/clinical-considerations/interimconsiderations-us.html#myocarditis-pericarditis. 90. Sularz AK, Hua A, Ismail T. SARS-CoV-2 vaccines and myocarditis. Clin Med (Lond), 2023;23(5):495-502.
RkJQdWJsaXNoZXIy MjI2NjI=